Neumora Therapeutics' Head of R&D Sells Over $490k in Company Stock
Neumora Therapeutics Analyst Ratings
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $23
Buy Rating on Neumora Therapeutics: Navigating Navacaprant's Potential in Neuropsychiatric Care
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
RBC Capital Reaffirms Their Buy Rating on Neumora Therapeutics, Inc. (NMRA)
Positive Week for Neumora Therapeutics, Inc. (NASDAQ:NMRA) Institutional Investors Who Control 42% of the Company
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD) and Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham
Express News | 5Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target
Neumora Therapeutics' Advancing Drug Pipeline Supports Buy Rating
Neumora Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Neumora Therapeutics' $371.6M In Cash, Cash Equivalents And Marketable Securities Expected To Support Operations Into 2026
Express News | Neumora Therapeutics Q2 2024 GAAP EPS $(0.37), Inline
Express News | Neumora Sees Cash, Cash Equivalents, Marketable Securities as of June 30 to Fund Ops Into 2026
Express News | Neumora: Q2 EPS -$0.37
Express News | Neumora: Narrowing Guidance to Submit an Ind for an Additional M4 Compound in H1 2025
Neumora Therapeutics 2Q Loss/Shr 37c >NMRA
Express News | Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update